Elanco Rises 3.4% as Bank of America Names It Sector’s Top Pick Ahead of Q2 Earnings

Bank of America has named Elanco Animal Health its preferred animal health name heading into Q2 earnings, citing a clearer catalyst path and greater upgrade potential than sector peers Zoetis and IDEXX — yet even as Elanco shares climb to $26.39, some analysts warn that the stock trades approximately 69% above its assessed intrinsic value of $15.61, creating a tension between powerful momentum and stretched fundamentals that investors must now navigate as the broader sector faces falling vet traffic and rising drug competition.

Bank of America maintained neutral ratings on Zoetis and IDEXX Laboratories, citing weaker veterinary traffic — forecast to fall approximately 2% in fiscal 2026 — rising drug competition, and soft investor sentiment. Elanco, by contrast, was identified as having a clearer catalyst path and greater scope for estimate upgrades, a view reinforced by analysts at Stifel and KeyBanc following strong product momentum from Credelio Quattro and Zenrelia launches.

Elanco shares rose 3.4% to $26.39 on 29 July, extending an 83.4% twelve-month gain. MarketBeat records a consensus Strong Buy with a $29.86 target, while insiders including CEO Jeffrey Simmons and director Rajeev Modi made purchases in May with no reported selling.

However, GuruFocus assigns a GF Score of 66 out of 100, with momentum scoring a perfect 10 but valuation the weakest element. The company remains unprofitable and cash-flow negative, making traditional earnings multiples less meaningful. The valuation case rests primarily on sales-based comparisons and future execution against a raised full-year outlook.